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Ultrasensitive amplicon barcoding 
for next-generation sequencing 
facilitating sequence error and 
amplification-bias correction
ibrahim Ahmed1,2, Felicia A. tucci3, Aure Aflalo1,4, Kenneth G. C. Smith1,5 & 
Rachael J. M. Bashford-Rogers1,3 ✉
The ability to accurately characterize DNA variant proportions using PCR amplification is key to many 
genetic studies, including studying tumor heterogeneity, 16S microbiome, viral and immune receptor 
sequencing. We develop a novel generalizable ultrasensitive amplicon barcoding approach that 
significantly reduces the inflation/deflation of DNA variant proportions due to PCR amplification biases 
and sequencing errors. This method was applied to immune receptor sequencing, where it significantly 
improves the quality and estimation of diversity of the resulting library.
Amplicon sequencing is often the basis for characterizing DNA variant proportions, and is routinely used in 
many areas including tumor heterogeneity1, 16S microbiome2, viral3, CRISPR/Cas9 library screens4 and immune 
receptor sequencing5. However, the ability to accurately quantify the proportions of DNA variants is hampered 
by amplification biases that lead to inflation/deflation of some DNA amplicons, as well as the inability to correct 
sequencing errors (Fig. S1a). To overcome the amplification biases in DNA-based amplification and sequencing, 
we developed a novel generalizable ultrasensitive amplicon barcoding approach that significantly reduces the 
inflation/deflation of DNA variant proportions from PCR amplification biases and sequencing errors.
Amplification biases from RNA starting material have been largely addressed by the introduction of unique 
molecular identifiers (UMIs) in the reverse transcription primers (barcoded primers), thus subsequent PCR 
amplification of each cDNA molecule can be quantified and corrected through the capture of the UMI barcode. 
However, when starting from a DNA template, this approach cannot be used. Previous attempts at generating 
barcoded PCR amplicons from DNA using barcoded primers via standard exponential PCR amplification leads 
to the preferential amplification of PCR amplicons rather than template6 and thus resulting  in significant ampli-
fication biases (Fig. S1b).
To overcome these issues, we established a sUMI-seq PCR amplification using barcoded primers that generate 
self-annealing amplicons (Fig. 1a, denoted sUMI-seq primers. Secondary structure-assisted UMI incorporation, 
amplification and sequencing). These sUMI-seq primers contain three key regions: (1) the target gene-specific 
region, (2) a UMI primer barcode (8 bp), and (3) a region based on multiple annealing and looping-based ampli-
fication cycles (MALBAC) methodology7, in which the PCR products are able to self-anneal forming MALBAC 
amplicon loops. These amplicon loops preferentially do not further amplify due to the thermodynamic and 
kinetic preference for loop closure compared to further primer annealing to the open and available original DNA 
template (Fig. S2). This will result in a close-to-linear amplification, rather than standard exponential ampli-
fication, of template DNA due to the unavailability of the MALBAC amplicon loops to further amplify. This 
first PCR (PCR1) is followed by a cleanup step to remove unbound primers and primer dimers. Then a second 
PCR (PCR2), with primers annealing to the common MALBAC region of PCR1 amplicons, generates linearized 
amplicons that are amenable for library preparation and high-throughput sequencing. A bioinformatics pipeline 
was developed to identify the primer barcodes, to correct for amplification frequency and to correct sequencing 
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errors through alignment of sequences sharing the same barcode (code made available at https://github.com/
rbr1/sUMI_processing_pipeline).
sUMI-seq is made possible by two key innovations: firstly, the PCR amplification step (PCR1) using the 
sUMI-seq primers allows for preferential amplification of the template DNA and minimal amplification of the 
MALBAC looped amplicons. Secondly, linearization of the self-annealed PCR amplicons in PCR 2 leads to 
increased sensitivity in the face of low template DNA input. The use of barcoded sample primers in PCR2 allows 
for sample pooling, and efficient library preparation and sequencing.
One area in which quantification of DNA variants is important is in B cell receptor sequencing. B cell recep-
tors (BCRs) are membrane-bound immunoglobulins (Igs) which are secreted as antibodies by antibody secreting 
Figure 1. Schematic of the sUMI-seq PCR with DNA molecular barcoding approach. (a) Schematic diagram 
of sUMI-seq. Quantification of pools of DNA variants can be important across multiple fields in biology, 
including B cell receptor (BCR) repertoire sequencing. MALBAC-barcoded primer design is shown. Amplicons 
from PCR1, after a clean-up step, are amplified in PCR2 using forward primers priming gene specific regions 
(as in PCR1) and reverse universal primers binding to the MALBAC regions (b) Schematic diagram of BCR 
rearrangement: B cells are generated from haematopoietic stem cells. The IGH gene locus on chromosome 14 
(in humans) encodes for multiple distinct copies of the variable (V), diversity (D), and joining (J) genes, with 
functional IGH BCR (one functional allele per cell) generated during B cell differentiation by site-specific V-D-J 
recombination. Random deletions and insertions of nucleotides during recombination results in sequence 
diversification at the gene junctional regions. Rearranged BCR genes can be further diversified through somatic 
hypermutation (SHM) upon B cell activation. (c) A BCR repertoire is defined as the BCRs collection from 
a B cell population, such as from blood or tissues. B cell DNA can be used to construct BCR libraries, using 
multiplex PCR with forward primers annealing to all the variable VH gene families (IgH V1–7) and reverse 
primers annealing to the JH gene families (IgH J1-6).
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cells (plasma cells), which differentiate from naïve or memory B cells upon antigen activation. The huge diversity 
of the antibody repertoire is due to DNA recombination of variable gene segments (V, (D), J) at the Ig heavy 
(IgH) and light (IgL) chain loci during B cell ontogeny, and subsequent acquisition of somatic hypermutation 
(SHM) in activated B cells. Both IgH and IgL variable regions are further subdivided into four framework regions 
(FWR 1–4), determining the antibody folding, and into three complementarity determining regions (CDR 1–3), 
involved in antigen binding. BCRs represent unique markers for each B cell clone (Fig. 1b,c). The BCR repertoire 
analysis by BCR gene deep sequencing allows measurement of the diversity and complexity of B cell response, 
and to identify clonal related B cells (B cell clones) which correlate with different immunological conditions. 
BCR repertoire analysis from blood or tissues by high-throughput sequencing has been used to provide power-
ful insights into B cell biology and tracking B cell clones in the context of health6,8, autoimmunity9, cancer10,11, 
infection12, vaccination13 and in other diseases. BCR sequencing from RNA has been established using UMIs of 
each RNA molecule to accurately quantify relative BCR RNA frequencies6. Despite the successes of RNA-based 
BCR repertoire sequencing, RNA can be a sub-optimal substrate for BCR sequencing. The level of Ig transcripts 
is upregulated through B cell maturation and activation upon antigen encounter, with plasma cells having the 
highest amount of Ig mRNA per cell. This may lead to inflation or deflation of the detected B cell clonotypes of a 
repertoire. This was shown clearly in the detection of B cell acute lymphocytic leukaemia10, where lower numbers 
of BCR RNA molecules per leukemic cell compared to non-leukemic B cells lead to a significant underrepresenta-
tion of patient tumor proportion. This major limitation can be overcome through sequencing from DNA, as B 
cells carry one functional BCR allele per cell (one B cell – one antibody). However, no reliable method for molec-
ular barcoding during PCR amplification of DNA has yet been established, thus leading to potential amplification 
biases in the resulting sequencing data.
Here we develop and validate a novel generalizable ultrasensitive amplicon barcoding approach and apply it 
to BCR sequencing, where it significantly improves the quality and estimation of diversity of the resulting library.
Results and Discussion
To test the effectiveness of sUMI-seq PCR, a synthetic DNA fragment library was designed containing an internal 
DNA barcode (referred to as synthetic DNA-UMI) unique to each DNA molecule (Figs. 2a, S3). This synthetic 
DNA fragment UMI library design was based on a BCR sequence. This means that both the synthetic DNA-UMI 
and BCR repertoire from clinical samples can be amplified using the same primer sets. Specifically, forward prim-
ers anneal to the IgH V genes (FR3) and reverse primers anneal to IgH J genes (Table S1), allowing the amplifi-
cation of the IgH variable region encompassing the CDR3 which is the major determinant of antibody-binding 
specificity (Fig. 5ci). Together, this synthetic DNA fragment UMI library design facilitates quantification of the 
relative amplification of each unique DNA template between methods. The sUMI-seq PCR was applied to the 
synthetic DNA fragment library using either 5, 10, or 20 PCR cycles in PCR1, to test the effect of different PCR 
cycles, followed by PCR2 (20 cycles). In addition, a standard non-barcoded PCR using standard non-barcoded 
primers (i.e containing the gene-specific annealing region only), using the same synthetic DNA-UMI as template, 
was amplified with an equivalent approach (see methods). Each reaction condition successfully generated PCR 
amplicons that were subsequently sequenced by MiSeq (sequencing information in Table S2).
Firstly, we quantified the frequency of further amplification of PCR1 self-annealing MALBAC loops prod-
ucts depending on the number of PCR cycles. This is achieved through the assessment of the frequencies of the 
synthetic DNA-UMI per primer barcode pair (i.e. 1000*(“number of identical synthetic DNA-UMIs”/“number 
of sUMI-seq primer barcode pairs”), (Fig. 2b). As expected, the frequency of duplicated synthetic DNA-UMIs 
per sUMI-seq primer barcode pair was low (mean rate per sample of 0.392–1.335 per 1000 reads). The rate of 
duplicated synthetic DNA-UMIs per sUMI-seq primer barcode pair increased with the number of PCR 1 cycles 
that appeared to asymptote at 1.291 (Fig. 2b, 75% confidence intervals 0.939–2.536, p-value = 0.0168). This 
demonstrated only a low level of further amplification of the MALBAC loop amplicon in PCR1, and this level can 
be tailored depending on the number of PCR cycles. Importantly, between 5–10 cycles and between 10–20 cycles, 
less that a 2-fold increase in MALBAC-loop-specific amplification was observed. This suggests that the PCR1 
step MALBAC-loop-specific amplification is non-exponential, and the PCR 1 step predominantly amplifies the 
original DNA template.
Next, we quantified and compared the relative amplification biases between sUMI-seq and standard 
non-barcoded PCR through synthetic DNA-UMIs amplification. To determine the effectiveness of the sUMI-seq 
primers in reducing the amplification biases, we also compared the relative amplification biases after filtering 
using or ignoring the sUMI-seq barcode information (Fig. 2ci). To account for differences in read depths between 
the different methods, each filtered dataset was subsampled to the same read depth across all samples (3000 
reads), and relative amplification biases were calculated, defined as the maximum number of reads containing the 
same synthetic DNA-UMI. The mean relative amplification biases was calculated from 500 repeats per sample. 
(Fig. 2cii). Indeed, the mean relative biases were equivalent between sUMI-seq PCR ignoring the barcode infor-
mation and the standard non-barcoded PCR. However, the mean relative biases were significantly lower in the 
sUMI-seq PCR using the barcode information compared to ignoring the barcode information (p-value=0.005). 
Together, this highlights the need for accounting for amplification biases.
Finally, a quantitative amplicon barcoding method should have a linear correlation between DNA template 
input and sequence output. To test this, we performed a dilution series of a peripheral blood (PB) DNA sample 
mixed with the synthetic UMI-DNA library at varying ratios, and sUMI-seq PCR was applied, again using either 
5, 10, or 20 PCR1 cycles (Fig. 3a). The PB DNA sample was from a chronic lymphocytic leukaemia (CLL) patient, 
characterised by a clonal expansion of a single B cell clone, where >50% of all peripheral B cells contain a sin-
gle IgH VDJ rearrangement (IGHV1–69*14-IGHJ6*02), as previously published5. Indeed, there was a strong 
linear relationship between CLL DNA input and proportion of sequencing reads after accounting for barcodes 
(Figs. 3b,c, S4). This suggests that sUMI-seq primers can be used to accurately correct amplification bias.
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We next applied sUMI-seq PCR to BCR sequencing of clinical samples, namely on a well-characterized cohort 
of peripheral blood mononuclear cell (PBMC) samples from 11 healthy individuals and 4 chronic lymphocytic 
leukemia (CLL) patients who have previously been sequenced using the conventional BCR non-barcoded ampli-
fication method14. Subsequent linearization of the amplicons in PCR2 with the inclusion of a sample-specific 
barcode in the linearization primers was used to facilitate efficient sample pooling before library preparation and 
high-throughput sequencing (Fig. 4a). This yielded between 4228–29372 unique sUMI-barcodes per sample after 
filtering for BCRs, comprising between 1055–4688 unique IgH V-D-J rearrangement per sample (Table S1). As 
previously observed, the healthy individual samples yielded diverse BCR repertoires (Figs. 4b and S6), whereas 
the CLL samples were characterized by the clonal expansion of a single malignant B cell clone (Fig. 4b), demon-
strated by the increased maximum clone size and clonal diversification indices. The BCR sequences of dominant 
malignant BCR clones identified by sUMI-seq were identical to that of conventional BCR non-barcoded ampli-
fication methods and BCR amplification by RNA as previously published5 (Fig. S7). Furthermore, the frequency 
Figure 2. sUMI-seq more accurately quantified B cell receptor sequence repertoires. (ai) Schematic diagram of 
the synthetic barcoded DNA fragments (representing a BCR sequence) used to quantify the DNA capture and 
amplification biases of DNA sequencing methods. A library of synthetic DNA fragments was designed based 
on a BCR sequence and containing a region of random nucleotides such that each DNA fragment is unique 
(termed synthetic DNA-UMIs). These were amplified using the sUMI-seq primers (ai,aii) and standard PCR 
primers with gene specific sequences. (b) Quantifying the frequency of further amplification of that PCR1 self-
annealing MALBAC loops products under 5, 10 and 20 PCR 1 cycles performed in duplicate. (c) Quantification 
of the amplification bias using synthetic DNA-UMIs and sUMI-seq compared to standard PCR amplification. 
(i) Schematic diagram of the experimental design and (ii) a boxplot of the mean relative amplification biases 
between sUMI-seq (filtering using barcode information), sUMI-seq (filtering ignoring barcode information), 
and standard PCR amplification without barcodes. The number of samples per box is provided in brackets. 
Wilcoxon tests were performed in R.
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of each B cell clone, as defined by the CDR3 of the BCR sequence, was highly correlated with that of the conven-
tional DNA amplification method (Fig. 4c). Together, this demonstrated that sUMI-seq PCR could be used to 
efficiently capture BCR repertoire data from DNA sources.
We next determined whether the capture of BCR repertoires were significantly improved using sUMI-seq. 
Given that sUMI-seq benefits from both error-correction and amplification bias-correction (see methods), we 
hypothesized that the estimation of (1) clonal diversity, (2) the level of somatic hypermutation and (3) mean 
amplicon length would be improved compared to standard non-barcoded BCR PCR amplification methods.
Firstly, the relative clonal diversity of all clones representing>1% of the total repertoire in each sample was 
compared between filtering using sUMI-seq barcode information to correct for amplification biases and filtering 
ignoring the sUMI-seq barcode information, whilst accounting for read depth (Fig. 5a,bi). Indeed, the use of 
the sUMI-seq barcode information resulted in a significant reduction in estimated clonal diversity in all clones 
tested in both healthy (diverse) and CLL (clonal) BCR repertoires (p-values < 1e-10, Fig. 5bii). This suggests 
that standard PCR amplification methods overestimate the diversity of DNA pools due to the introduction of 
PCR amplification and sequencing errors, which can be corrected through the use of sUMI-seq primer barcod-
ing. Secondly, the estimation of the level of somatic hypermutation (SHM) was significantly reduced when the 
sUMI-seq barcode information was used for filtering. This was demonstrated by a significantly higher proportion 
of unmutated BCR sequences (i.e. the IGHV region within 1 bp difference from the closest germline reference 
gene) when using the sUMI-seq primer barcoding (Fig. 5cii). The nature of the mutations, often reported in BCR 
sequencing studies15, was also significantly different when using error and amplification bias correction. This was 
shown both in terms of the lower silent-to-non-silent mutation ratio (p-value = 0.033, Fig. 5biii) and the loca-
tions of the mutations: namely a higher proportion of mutations occurring in the CDRs compared to the FWRs 
(p-value = 0.00059, Fig. 5civ). The latter is in agreement with previous studies where mutations are known to 
preferentially occur in the CDRs compared to the FWRs16,17.
Furthermore, the PCR amplification is known to preferentially amplify shorter amplicons. The CDR3 is the 
most variable region of the BCR sequence, driven in part by the combinations of different IGHV-D-J regions that 
are recombined during B cell maturation (Fig. 5ci). Indeed, longer CDR3 lengths (longer than ~20 amino acids) 
are associated with both auto- and poly-reactivity and are often interrogated in BCR repertoire studies18. The 
mean CDR3 region length can be determined from the BCR sequencing data, and, indeed, significantly increased 
mean CDR3 lengths were observed using amplification-bias-correction via sUMI-seq compared to when error 
correction was not used (Fig. 5cv).
Together, this data suggests that the sUMI-seq barcoded approach represents a closer representation of the 
“ground truth” of the BCR repertoire compared to the non-barcoded repertoires. This demonstrates that the 
estimation of diversity, mutation and amplicon lengths of a mixed DNA pool are all significantly improved by 
sUMI-seq compared to conventional non-barcoded methods.
In summary, the sUMI-seq strategy allows for ultrasensitive barcoding of PCR amplicons from DNA for 
high-throughput sequencing, benefiting from significantly reduced PCR and sequencing errors and amplification 
biases leading to more accurate characterization of mixed DNA samples. We applied this method to immune 
receptor repertoire (BCR) profiling, where sUMI-seq captured both highly diverse and highly clonal B cell rep-
ertoires from healthy and CLL patients, respectively. sUMI-seq allowed for more accurate estimation of diversity, 
mutation and amplicon lengths, which are key analyses in many studies of mixed DNA variant pools. sUMI-seq 
can be easily applied to any PCR amplicons, and benefits from simplicity of primer design, straightforwardness of 
the amplification protocol with few steps, and streamlined method for incorporating sample barcodes in the sec-
ond PCR. We have demonstrated the utility and power of this method in the characterization of complex immune 
receptor repertoire profiles, and this may be applied to a wide range of other applications in which characterizing 
DNA variants may be obscured by amplification bias or sequence error.
Materials and Methods
Samples. Peripheral blood mononuclear cells (PBMCs) were isolated from 10 mL of whole blood from 
healthy volunteers and CLL patients using Ficoll gradients (GE Healthcare). Total RNA was isolated using TRIzol 
and purified using RNeasy Mini Kit (Qiagen), including on-column DNase digestion according to the manufac-
turer’s instructions. Ethical approval for this study was obtained from the Eastern NHS Multi Research Ethics 
Committee (07/MRE05/44). Informed consent was obtained from all subjects enrolled and all experiments were 
performed in accordance with relevant guidelines and regulations.
Design and amplification with barcoded primers. Gene specific sUMI-seq primers were designed 
according to Fig. S8.
sUMI-seq PCR 1 amplification with barcoded MALBAC primers. PCR1 was performed using 15 μL KAPA buffer 
(2×) (KAPA HIFI Hotstart PCR kit, Kapa Biosystems), 1 μL MALBAC IgH V (FR3) forward primer mix (10 µM) 
(containing 7 family specific primers designed to target the FR3 regions of VH1 through VH7 variable gene fam-
ilies) and 1 μL MALBAC reverse primer JH_(10 µM) (consensus sequence), 8 μL nuclease-free water, 5 μL DNA 
template (20 ng/μL), in a final volume of 30 μL. sUMI-seq primer sequences that amplify the BCR repertoire 
are provided in Table S1. The synthetic DNA library (UMI_DNA) was designed to be amplified with the same 
primer sets. The thermal cycling conditions for sUMI-seq PCR 1 were as follows: 1 cycle (95 °C–5 min); 5 cycles 
(98 °C–5 sec; 72 °C–2 min); 5 cycles (65 °C–10 sec, 72 °C–2 min); 5, 10, 20, or 30 cycles (98 °C–20 sec, 60 °C–1 min, 
72 °C–2 min); 1 step (72 °C–10 min). PCR1 amplicons were then cleaned-up using 0.8x Agencourt AMPure XP 
beads (Beckman Coulter).
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sUMI-seq PCR 2 amplification (without sample IDs). The PCR2 reaction was performed using 17.5 μL of KAPA 
buffer (2×) (KAPA HIFI Hotstart PCR kit, Kapa Biosystems), 1 μL of 10 μM IgH V (FR3) forward primer mix and 
1 μL of 10 μM MALBAC_UNI primers, 5.5 μL of nuclease-free water, 10 μL of DNA template (from PCR1), in a 
final volume of 35 μL. The thermal cycling conditions were as follows: 1 cycle (95 °C–5 min); 5 cycles (98 °C–5 sec; 
72 °C–2 min); 5 cycles (65 °C–10 sec, 72 °C–2 min); 20 cycles (98 °C–20 sec, 60 °C–1 min, 72 °C–2 min); 1 step 
(72 °C–10 min).
sUMI-seq PCR 2 amplification (with sample barcode IDs). The PCR2 reaction was performed using 17.5 μL 
KAPA buffer (2×) (KAPA HIFI Hotstart PCR kit, Kapa Biosystems), 1 μL MALBAC IgH V (FR3) forward 
primer mix (10 μM), and 1 μL MALBAC_UNI_Ind primer (10 μM) (choice of 1–12 barcodes) (Table S1), 5.5 μL 
nuclease-free water, 10 μL DNA template (from PCR1), for a total volume of 35 μL. The thermal cycling conditions 
were as follows: 1 cycle (95 °C–5 min); 5 cycles (98 °C–5 sec; 72 °C–2 min); 5 cycles (65 °C–10 sec, 72 °C–2 min); 20 
cycles (98 °C–20 sec, 60 °C–1 min, 72 °C–2 min); 1 step (72 °C–10 min).
Standard non-barcoded PCR amplification. This was performed using 15 μL KAPA buffer (2×) (KAPA 
HIFI Hotstart PCR kit, Kapa Biosystems), 1 μL IgH V (FR3) forward primer mix (10 μM) (standard non-barcoded 
primers), and 1μL reverse IgH-J (10 μM) (standard primers), 8 μL nuclease-free water, 5 μL DNA template (20 ng/
μL), for a total volume of 30 μL. The thermal cycling conditions were as follows: 1 cycle (95 °C–5 min); 5 cycles 
(98 °C–5 sec; 72 °C–2 min); 5 cycles (65 °C–10 sec, 72 °C–2 min); 5, 10, or 20 cycles (98 °C–20 sec, 60 °C–1 min, 
72 °C–2 min); 1 step (72 °C–10 min).
High-throughput sequencing and QC. PCR2 DNA amplicons were cleaned-up using 0.8x Agencourt 
AMPure XP beads (bead-based size selection) and checked using electrophoresis on a 2% agarose gel. MiSeq 
libraries were prepared using KAPA protocols (KK8722 and KK8504) and sequenced using 300 bp pair-end 
MiSeq (Illumina). Raw MiSeq reads were filtered for base quality (median Phred score >32) using QUASR 
(http://sourceforge.net/projects/quasr/)3.
MiSeq forward and reverse reads were merged together if they contained an identical overlapping region of 
>50 bp, or otherwise discarded.
For the sUMI-seq filtering pipeline. Universal barcoded regions were identified in reads and orientated 
to read from forward (IgH V)-primer to reverse (IgH-J) region primer. The barcoded region within each primer 
was identified and checked for conserved bases. Error-correction and amplification bias correction: Groups 
of sequencing reads containing the same sUMI-seq primer UMIs originate from the same DNA template, and 
therefore a consensus sequence was generated from these groups. This reduces amplification biases (i.e. the effect 
of differential amplification of DNA templates), as well as correcting potential PCR/sequencing errors. Consensus 
sequences were retained only if there was a per-base agreement of 80% between all sequencing reads containing 
the same UMI. For groups of 4 of fewer sequencing reads containing the same UMI, there needed to be complete 
agreement between sequences after alignment, otherwise were discarded. This is summarised in Fig. S5.
Figure 3. Titration of DNA pools using sUMI-seq. PCR (a) Schematic of titration experiment: To test the 
quantitative nature of sUMI-seq, a dilution series was performed of a peripheral blood (PB) DNA sample, from 
a chronic lymphocytic leukaemia (CLL) patient, mixed with the synthetic barcoded BCR DNA fragment library 
at varying ratios. sUMI-seq PCR was applied, again using either 5, 10, or 20 cycles in PCR1. (b) DNA agarose 
gel showing the BCR amplification of a titration of a CLL patient PB DNA sample into synthetic barcoded BCR 
fragments using 5 cycles in PCR1 and (c) the corresponding linear correlation between CLL DNA patient input 
and proportion of CLL BCR sequencing reads after accounting for primer barcodes based on PCR1 cycles.
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For the standard filtering pipeline. The primer regions within the sequencing reads were determined. All 
sequences without identifiable primer annealing regions were discarded.
Quantifying the frequency of further amplification of that PCR1 self-annealing MALBAC loops 
products. For each sequence within the synthetic UMI-DNA datasets, the synthetic DNA-UMIs and primer 
barcode pairs were identified. From this, the proportion of sequences which contained DNA-UMIs associated 
with more than one primer barcode pairs was determined, and normalised to the total number of reads (provided 
as a rate per 1000 reads): ∗ − ∗ −
−( )1000 number of identical synthetic DNA UMIs number of sUMI seq primer barcode pairsnumber of BC MALBAC primer pairs / number of reads
Quantifying amplification bias using the synthetic DNA-UMIs library and comparing sUMI 
PCR to standard PCR amplification. The relative amplification biases were compared between (1) 
the sUMI-seq method using sUMI-seq barcode information (using the sUMI-seq filtering pipeline), (2) the 
sUMI-seq method ignoring the sUMI-seq barcode information (using the standard filtering pipeline), and (3) 
using the standard non-barcoded PCR amplification method and the standard filtering pipeline. To account for 
differences in read depths between the different methods, each filtered dataset was subsampled to the same read 
Figure 4. BCR repertoire sequencing by sUMI-seq. PCR (a) Schematic diagram of multiplex (sample-
barcoded) sUMI-seq. used in PCR2 (b) Representative network plots of 2 chronic lymphocytic leukaemia 
(CLL) and 2 healthy individual BCR repertoires derived from PBMC DNA amplified by (top) the standard 
non-barcoded BCR amplification approach and (bottom) by sUMI-seq. Each vertex represents a unique 
BCR sequence (B cell clone), where relative vertex size is proportional to the number of identical BCR reads. 
Edges join vertices that differ by single nucleotide non-indel differences and clusters are collections of related, 
connected vertices. Networks are comprised of a subsample of 500 BCRs per sample. (c) Correlation of the 
frequencies of each B cell clone (defined by the CDR3 sequence) within the CLL patient samples derived from 
the sUMI-seq method versus the standard PCR method. The grey dotted line corresponds to y = x, and each 
point corresponds to a different CDR3 (B cell clone) sequence frequency.
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depth across all samples (3000 reads), defined as the maximum number of reads containing the same synthetic 
DNA-UMI:
=amplification bias per subsample max n( ) ( )i
where ni is number of reads containing synthetic DNA − UMI i. The mean relative amplification biases was cal-
culated from 500 repeats per sample. Wilcoxon tests were performed in R.
BCR sequence filtering. Sequences without complete reading frames and non-immunoglobulin sequences 
were removed and only reads with significant similarity to reference IgH variable genes (V-D-J) from the IMGT 
database were retained using BLAST19. Sequence annotation, including somatic hypermutation, CDR3 regions 
and IGHV gene usages, were defined via IMGT V-QUEST, where repertoire differences were performed by cus-
tom scripts in Python, and statistics were performed in R using Wilcoxon tests for significance.
Figure 5. Comparison of BCR repertoire features between sUMI-seq PCR, filtering with and without barcode 
information (a) Schematic diagram of the comparison between sUMI-seq (filtering using barcode information) 
and sUMI-seq (filtering ignoring barcode information). (bi) Quantifying the mean intraclonal diversity: the 
relative intraclonal diversity of all clones >1% of the total repertoire in each sample was compared between 
the two methods. To account for the differences in read depth, the BCRs from each clone were subsampled to 
a fixed depth between filtering methods (0.75x the minimum number of sequences per clone across methods). 
The relative intraclonal diversity of each clone was defined as number of unique BCR sequences per clone after 
subsampling, and the mean intraclonal relative intraclonal diversity was determined through calculating the 
mean of 50 repeats. (ii) Boxplots of the mean intraclonal diversity between methods for all healthy (left) and 
CLL (right) patient samples, plotted on a logarithmic scale. Grey lines connect the mean relative clonal diversity 
measurements between methods. (ci) The schematic demonstrates the relative locations of the CDRs and FWRs 
within the BCR sequences (IgH VDJ). Boxplots quantify the differences in commonly used BCR repertoire 
features between methods including (cii) the proportion of unmutated BCRs (i.e. BCRs with no somatic 
hypermutations), (ciii) the ratio of silent-to-non-silent mutations, (civ) the CDR/FWR mutation ratio and (cv) 
CDR3 lengths (amino acids). The y axis provides the mean value per sample for each BCR repertoire feature, 
and grey lines the measurements between methods. Wilcoxon tests were performed in R.
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BCR repertoire generation and network analysis. The network generation algorithm and network 
properties were calculated as in Bashford-Rogers et al.5: each vertex represents a unique sequence, where relative 
vertex size is proportional to the number of identical reads. Edges join vertices that differ by single nucleotide 
non-indel differences and clusters are collections of related, connected vertices.
A clone (cluster) refers to clonally-related B cells, containing BCRs with identical CDR3 regions and IgH gene 
usage, or differing by single point mutations, such as through somatic hypermutation.
Clonality diversity refers to the relative number of clonally-related, but distinct, B cells within a clone. In the 
context of BCR sequencing, this is a measure of the number of unique clonally-related BCRs (clone members). 
Sequence repertoire parameters that were dependent on sequencing depth were generated by subsampling each 
sequencing sample to a specified clone depth. This includes the Clonal Diversification index, was measured by 
cluster Renyi Index as defined in Bashford-Rogers et al.5. This is calculated from the distribution of the number 
of unique VDJ region sequences per clone within subsampled BCR repertoires at specified depth of 1000 clones. 
The mean of 100 repeats of resulting Clonal Diversification indices was determined. Clone size distributions were 
also calculated from the same subsamples and a mean of 100 repeats was determined.
BCR network sampling to preserve the overall clonal structure of visual representation. To 
obtain representative subgraph of a network that preserves the overall relative clonal architecture whilst pro-
viding visual representations that distinguish between samples of different clonalities, clone subsampling was 
used as described in15. One thousand clones are subsampled and a network generated from all BCRs from these 
clones. Subsampling was performed 100 times, and the sample that contained a maximum clone size closest to the 
median of all subsamples greater than the unsampled maximum clone size was chosen.
Ethics approval and consent to participate. Ethical approval for this study was obtained from the 
Eastern NHS Multi Research Ethics Committee (07/MRE05/44). Informed consent was obtained from all sub-
jects enrolled.
Data availability
Code is made available at https://github.com/rbr1/sUMI_processing_pipeline. The datasets used and/or analysed 
during the current study are available from the corresponding author on reasonable request. All sequencing data 
will be uploaded to the EGA.
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